Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results
04 mars 2021 16h15 HE
|
Onconova Therapeutics, Inc.
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021 NEWTOWN, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a...
Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March
01 mars 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, PA., March 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement
24 févr. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option
16 févr. 2021 16h03 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference
16 févr. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
10 févr. 2021 16h01 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
14 janv. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
21 déc. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
23 nov. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
U.S. Phase 1 trial patient enrollment to begin in the first half of 2021China Phase 1 trial enrollment ongoingKey regulatory milestone achieved to enable further study of product candidate for...
Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
12 nov. 2020 16h05 HE
|
Onconova Therapeutics, Inc.
ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumorsInvestigator-initiated study advances with combination of oral rigosertib and nivolumab in K-RAS...